Iverscab (Ivermectin)

Ivermectin works by binding to glutamate‑gated chloride channels that are present in the nerve and muscle cells of parasites. This binding opens the channels, allowing an influx of chloride ions, which hyperpolarises the cells, leading to paralysis and death of the parasite while sparing human cells that lack these channels.

The dose of Iverscab is determined by the prescribing clinician based on the specific infection being treated, the patient’s age, weight, renal and hepatic function, and any relevant clinical guidelines. No standard dose is provided here; the prescriber will calculate the appropriate regimen for each individual case.

Safety data for ivermectin in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against possible risks before prescribing Iverscab to pregnant or nursing women. If treatment is essential, it may be used under close medical supervision, but alternative therapies are considered when possible.

To order Iverscab, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any necessary import documentation.

Iverscab (ivermectin) offers a broad‑spectrum oral option that is effective against many nematodes and ectoparasites, often with a convenient single‑dose regimen. Compared with other classes such as benzimidazoles or praziquantel, ivermectin has a distinct mechanism of action and may be preferred for infections like onchocerciasis and scabies, while other agents may be chosen for different parasite species or resistance patterns.

Iverscab should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture, light and excessive heat. Do not store in a refrigerator or freezer unless specifically instructed by the manufacturer.

Iverscab is taken orally, usually as a whole tablet with water. The exact timing (e.g., with or without food) and frequency depend on the indication and the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and complete the full course of therapy.

Serious adverse events, although rare, include severe skin reactions such as Stevens‑Johnson syndrome, hepatotoxicity manifested by elevated liver enzymes or hepatitis, and neurologic effects like seizures, ataxia or altered consciousness. Patients should seek immediate medical attention if they experience rash, jaundice, severe abdominal pain, visual changes, or neurological symptoms.

Iverscab should be avoided in individuals with a known hypersensitivity to ivermectin or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, those taking strong CYP3A4 or P‑glycoprotein inhibitors, and individuals with a history of neurologic disorders that could be exacerbated by the drug.